CG Oncology initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado initiated coverage of CG Oncology with a Buy rating and $75 price target. Despite recent approvals, the treatment of non-muscle invasive bladder cancer remains a high unmet medical need, the analyst tells investors in a research note. The firm says CG Oncology’s late-stage asset cretostimogene has the potential to traverse the various subtypes and patient groups within NMIBC, opening the door to a billion-dollar market opportunity.